Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Anum Glasgow; Jeff Edward Glasgow; Daniel Limonta; Paige Solomon; Irene Lui; Yang Zhang; Matthew A Nix; Nicholas J Rettko; Shion A Lim; Shoshana Zha; Rachel Yamin; Kevin Kao; Oren S Rosenberg; Jeffrey V Ravetch; Arun P Wiita; Kevin K Leung; Xin X Zhou; Tom C Hobman; Tanja K Kortemme; James A. Wells.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-231746

Documentos relacionados

  1. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
  2. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
  3. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern.
  4. Mechanisms of SARS-CoV-2 entry into cells.
  5. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
  6. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
  7. Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants.
  8. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
  9. A novel consensus-based computational pipeline for screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including Omicron variant.
  10. Rapid Profiling of the Glycosylation Effects on the Binding of SARS-CoV-2 Spike Protein to Angiotensin-Converting Enzyme 2 Using MALDI-MS with High Mass Detection.